索拉非尼治疗晚期原发性肝癌的疗效和安全性分析

目的　评价索拉非尼治疗国人原发性肝癌的疗效和安全性。方法　总结２００８年１月至２００９年８月应用索拉非尼治疗的３７例原发性肝癌患者的临床资料，其中３例由于在服药后６周内死亡未进行肿瘤评价。结果　２８例采用ＲＥＣＩＳＴ标准评价，２４例获稳定，４例进展；８例ＥＣＯＧ体力状况评分改善；不良反应一般在服药后１～２周左右出现，３７例患者中１０例发生３～４级的不良反应，因不能耐受不良反应而减少药物剂量者７例，另３例停药。药物不良反应在减少剂量的基础上对症支持治疗后大多可以缓解。结论　索拉非尼可延长晚期原发性肝癌患者的肿瘤无进展生存时间，且耐受性良好，是治疗晚期原发性肝癌的新选择。

The efficacy of sorafenib in the treatment of hepatocellular carcinoma

Objective To evaluate the efficacy and safety of sorafenib in treatment of hepatocellular carcinoma.Methods From Jan.2008,to Aug.2009,37 patients with hepatocellular carcinoma were treated with sorafenib;their clinical data were retrospective1y analyzed.Three patients died within 6 weeks after sorafenib treatment and were excluded from this study.Results Twenty-eight patients received more than once of tumor assessment with RECIST criteria after six weeks;24 patients had stable condition and 4 patients had ...